ESMO 2022 | The evolving role of PARP inhibitors in mCRPC

Andrew Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, discusses advances in the use of PARP inhibitors such as olaparib in treating metastatic castrate-resistant prostate cancer (mCRPC), which have been proven efficacious in patients who progress from aromatase inhibitors and have BRCA2. Whilst patients with BRCA1 or PALB2 mutations may benefit less from PARP inhibitors, various trials including the PROpel (NCT03732820), MAGNITUDE (NCT03748641), AMPLITUDE (NCT04497844) and TALAPRO-1 (NCT03148795) trials will aim to investigate PARP inhibitors in combination therapies to improve their efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.